Business Context and Reporting Period
This Form 8-K reports the results of a Special Meeting of Stockholders held by Moleculin Biotech, Inc. on October 16, 2025. As of the record date (August 28, 2025), there were 36,739,360 shares of common stock outstanding. A quorum was established with 14,737,799 shares present in person or by proxy.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Three proposals were submitted to stockholders with the following outcomes:
- Proposal 1 (Approved): Stockholders approved the issuance of up to 64,864,864 shares of common stock upon the exercise of warrants issued on August 28, 2025, to satisfy Nasdaq listing requirements.
- Votes For: 4,937,555
- Votes Against: 1,479,087
- Abstain: 142,257
- Broker Non-Votes: 8,178,900
- Proposal 2 (Not Approved): Stockholders did not approve the amendment to change the company name from "Moleculin Biotech, Inc." to "Moleculin Inc." The proposal required a majority of outstanding shares to vote "For," which was not achieved.
- Votes For: 11,258,199
- Votes Against: 843,364
- Abstain: 2,636,236
- Broker Non-Votes: 0
- Proposal 3 (Approved): Stockholders approved an adjournment, if necessary, to solicit additional proxies for the Nasdaq Proposal or the Name Change Proposal.
- Votes For: 5,589,386
- Votes Against: 806,047
- Abstain: 163,466
- Broker Non-Votes: 8,178,900
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the context of the voting proposals. The approval of the adjournment (Proposal 3) indicates a contingency plan to seek further votes if necessary to address the Nasdaq listing requirements or the name change.
Investor Verification Checklist
- Verify the definitive proxy statement filed on September 15, 2025, for detailed terms of the warrant issuance.
- Confirm the specific Nasdaq listing rule that necessitated the warrant issuance approval.
- Monitor for any subsequent filings regarding the adjournment and potential re-vote on the name change proposal.
- Review the impact of the approved warrant issuance on potential future share dilution.